Compare Allstate Corp (ALL) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs BioNTech SE - ADR — how do they compare? Allstate Corp trades at $257.32 (market cap $66.31B), while BioNTech SE - ADR trades at $93.37 (market cap $23.31B). The key difference: Allstate Corp is far larger — about 2.8× BioNTech SE - ADR's market cap, and Allstate Corp pays a 1.65% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| ALL | BNTX | |
|---|---|---|
Market Cap | $66.31B | $23.31B |
Sector | Financials | Health |
52-Week High | $275.11 | $119.34 |
52-Week Low | $190.00 | $83.89 |
Enterprise Value | $74.96B | $6.60B |
Dividend Yield | 1.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $256.62, down 4.84% over 24 hours, but maintains a bullish technical signal with strong fundamental performance. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, with revenue growth and improved underwriting profitability. Recent news highlights institutional buying and positive analyst coverage, though some caution exists on sustainability.
The outlook remains positive with a consensus price target of $266.47, offering potential upside. Key risks include sustainability of underwriting margins and macroeconomic sensitivity. Earnings momentum and valuation metrics support a favorable investment case, but investors should monitor competitive pressures and catastrophe loss trends.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
